COVID-19: Overview of rheumatology fellows.
Reumatol Clin (Engl Ed)
; 17(9): 491-493, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1510266
ABSTRACT
SARS-COV-2 infection has spread worldwide since it originated in December 2019, in Wuhan, China. The pandemic has largely demonstrated the resilience of the world's health systems and is the greatest health emergency since World War II. There is no single therapeutic approach to the treatment of COVID-19 and the associated immune disorder. The lack of randomised clinical trials (RCTs) has led different countries to tackle the disease based on case series, or from results of observational studies with off-label drugs. We as rheumatologists in general, and specifically rheumatology fellows, have been on the front line of the pandemic, modifying our activities and altering our training itinerary. We have attended patients, we have learned about the management of the disease and from our previous experience with drugs for arthritis and giant cell arteritis, we have used these drugs to treat COVID-19.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Antivirales
/
Rol del Médico
/
Factores Biológicos
/
Reumatólogos
/
Tratamiento Farmacológico de COVID-19
/
Inmunosupresores
Tipo de estudio:
Estudio experimental
/
Estudio observacional
/
Estudio pronóstico
/
Ensayo controlado aleatorizado
Tópicos:
Covid persistente
Límite:
Humanos
País/Región como asunto:
Europa
Idioma:
Inglés
Revista:
Reumatol Clin (Engl Ed)
Año:
2021
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS